Clinical trials: Complication in Systemic Lupus Erythematosus
Lupus Nephritis
A Study to Compare the Efficacy and Safety of Tacrolimus Capsules and Cyclophosphamide Injection in Treatment of Lupus Nephritis
The objective of this study is to evaluate the efficacy and safety of Tacrolimus capsules for induction remission in patients with lupus nephritis, and compare the efficacy and safety with Cyclophosphamide injections.
- Trial name
- NCT02457221
- Testing
- Tacrolimus capsules, Cyclophosphamide injections, Prednisone
- Where
- 35 sites in China
- Volunteers
- 314 people
- Sponsor
- Astellas Pharma China, Inc.
Lupus Nephritis
RY_SW01 Cell Injection Therapy in Active Lupus Nephritis
RY_SW01 Cell Injection's preclinical research results have shown that the injection significantly improved urine biochemical indicators and tissue damage in two lupus nephritis animal models after MSC administration, with no…
- Trial name
- NCT06058078
- Testing
- RY_SW01 cell injection, Basic treatment
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Jiangsu Renocell Biotech Company
Lupus Nephritis (LN)
The Efficacy of Empagliflozin on Kidney Functions in Lupus Nephritis Population
Systemic lupus erythematosis (SLE) is a chronic, most probably auto-immune multisystem disease marked by relapsing-remitting course and the formation of a range of autoantibodies.
- Trial name
- NCT07700940
- Testing
- Empagliflozin (25 Mg Tab) along with standard medical therapy
- Where
- Egypt
- Volunteers
- 66 people
- Sponsor
- Ahmed Yehia Ismail
Raynaud Phenomenon Due to Trauma, Raynaud Disease
Topical 10 % Nifedipine Versus 5% Sildenafil in Secondary Raynaud
Objective: To compare the efficacy of topical 10% nifedipine versus 5% sildenafil in patients with secondary Raynaud's phenomenon (RP).
- Conditions
- Raynaud Phenomenon Due to Trauma, Raynaud Disease, System; Sclerosis, Lupus Erythematosus, Systemic
- Trial name
- NCT03027674
- Testing
- 10% nifedipine cream, 5% sildenafil cream
- Where
- Chile
- Volunteers
- 10 people
- Sponsor
- Pontificia Universidad Catolica de Chile
Lupus Nephritis
Zanubrutinib in Participants With Active Proliferative Lupus Nephritis
The primary objective of this study is to evaluate the efficacy of zanubrutinib added to standard of care as measured by complete renal response for participants with active proliferative lupus nephritis
- Trial name
- NCT04643470
- Testing
- Zanubrutinib
- Where
- 44 sites in China
- Volunteers
- 177 people
- Sponsor
- BeiGene
Atherosclerosis, Lupus Nephritis
Angiotensin-II Receptor Antibodies Blockade With Losartan in Patients With Lupus Nephritis
Antibodies directed against angiotensin-II receptor (AT1-Ab) are agonist antibodies previously studied in human diseases such as preeclampsia, transplantation and scleroderma.
- Trial name
- NCT03526042
- Testing
- Losartan, Enalapril
- Where
- Mexico
- Volunteers
- 40 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Refractory Systemic Lupus Erythematosus, Refractory Lupus Nephritis
NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis
This is an investigator-initiated, open-label, single-arm study to determine safety and preliminary efficacy of NK010 or NK042 in combination with rituximab (RTX) for the treatment of patients with refractory systemic lupus…
- Trial name
- NCT06676631
- Testing
- NK 010 or NK042, Rituximab
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Guangdong Provincial People's Hospital
Lupus Erythematosus, Systemic
Synergetic B-cell Immunomodulation in SLE - 2nd Study.
In follow-up of the previous SynBioSe Study the present study is a randomized controlled trial designed to further investigate the long-term clinical and imunological efficacy of combination B-cell targeting by starting treatment…
- Trial name
- SynBioSe-2 (NCT03747159)
- Testing
- Belimumab Injection
- Where
- 4 sites in Netherlands
- Volunteers
- 71 people
- Sponsor
- Leiden University Medical Center
Lupus Nephritis, IgA Nephropathy
The Correlation of Periostin and Renal Pathology in Chronic Kidney Disease Patients
The purpose of this study is to determine the location of periostin and urine periostin level in patients with lupus nephritis and IgA nephropathy.
- Trial name
- NCT02493101
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Chulalongkorn University
Nephritis, Lupus, Lupus Erythematosus, Systemic
A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment
The goal of this clinical trial is to learn if cenerimod, on top of regular treatment, works to treat active lupus nephritis in adults with systemic lupus erythematosus and active lupus nephritis.
- Trial name
- LUMIOS (NCT07201129)
- Testing
- Cenerimod
- Where
- 14 sites in United States
- Volunteers
- 300 people
- Sponsor
- Viatris Innovation GmbH
Lupus Nephritis, Immunosuppression
Sirolimus in Treatment of Proteinuric Flares of Lupus Nephritis
This a single-centre, one-arm, open-label pilot study. Eligible patients with mild proteinuric flares of lupus nephritis Class III/IV±V are received sirolimus without changing previous immunosuppressive medication during 12-week…
- Conditions
- Lupus Nephritis, Immunosuppression, Effect of Drug
- Trial name
- NCT04892212
- Testing
- Sirolimus
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
IgA Nephropathy, Lupus Nephritis
Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies
This is a Phase II trial assessing the safety and preliminary efficacy of daily APL-2 subcutaneous infusion administered for 16 weeks with a 6 month safety follow up, in patients with glomerulopathies
- Conditions
- IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, C3 Glomerulonephritis
- Trial name
- NCT03453619
- Testing
- APL-2
- Where
- 17 sites in United States
- Volunteers
- 21 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Lupus Nephritis
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
The purpose of this study is to evaluate the efficacy and safety of IV antifrolumab in adult patients with Active Proliferative Lupus Nephritis
- Trial name
- IRIS (NCT05138133)
- Testing
- Anifrolumab
- Where
- 164 sites in United States, Argentina and 22 more
- Volunteers
- 363 people
- Sponsor
- AstraZeneca
Lupus Nephritis
Steroids in the Maintenance of Remission of Proliferative Lupus Nephritis
There is debate as to whether long-term low-dose steroids such as prednisolone help to suppress relapses of systemic lupus erythematosus (SLE) in patients who are in remission from their lupus nephritis.
- Trial name
- SIMPL (NCT00539799)
- Testing
- prednisolone
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Systemic Lupus Erythematosus, Sjögren's Disease
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
The purpose of this study is to evaluate the safety and tolerability of BMS-986553, CD19 in vivo Chimeric Antigen Receptor (CAR) T cells, in participants with refractory autoimmune diseases including systemic lupus erythematosus…
- Conditions
- Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies
- Trial name
- NCT07873931
- Testing
- BMS-986553
- Where
- 23 sites in United States, Belgium and 4 more
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb
Systemic Lupus Erythematosus, Lupus Nephritis
An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus
The study is intended to assess safety, efficacy and cellular kinetics of YTB323 treatment in participants with severe refractory systemic lupus erythematosus.
- Trial name
- NCT05798117
- Testing
- YTB323
- Where
- 10 sites in Australia, France and 3 more
- Volunteers
- 21 people
- Sponsor
- Novartis Pharmaceuticals
Lupus Nephritis
Anti-alpha-actinin Antibodies and Lupus Nephritis Activity
Lupus nephritis (LN) develops in 30-60% of systemic lupus erythematosus (SLE) patients and remains a leading cause of morbidity, with 10-30% progressing to end-stage renal disease within 15 years.
- Trial name
- NCT07505576
- Testing
- renal biopsy, serum anti-alpha-actinin antibodies, CBC, serum creatinine and urea, estimated GFR, ESR, CRP, urine analysis, ANA, anti dsDNA, C3 & C4, serum albumin, 24-hrs urinary protein, and U. ACR
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Assiut University
Periodontal Disease, Periodontitis
Periodontal Disease in Rare Renal Disorders (PERIO-RA-RE)
This study aims to evaluate the burden and phenotypic spectrum of periodontal disease in patients with rare kidney disorders (such as Alport syndrome, Fabry disease, and tuberous sclerosis complex) and systemic lupus…
- Conditions
- Periodontal Disease, Periodontitis, CKD, Chronic Kidney Disease
- Trial name
- PERIO-RA-RE (NCT07575347)
- Testing
- Observational assessment
- Where
- Romania
- Volunteers
- 100 people
- Sponsor
- Stefan Lujinschi
Lupus Nephritis
BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis
The primary objective of the study is to assess the efficacy of BIIB023 as an add-on treatment to background therapy compared with placebo in combination with background therapy in the treatment of participants with active…
- Trial name
- ATLAS (NCT01499355)
- Testing
- BIIB023, mycophenolate mofetil, oral corticosteroids
- Where
- 58 sites in United States, Argentina and 19 more
- Volunteers
- 276 people
- Sponsor
- Biogen
Lupus Nephritis
The Expression Profile of New Complement Components in Childhood Lupus Nephritis
The aim of this study was to evaluate whether C4d is a better biomarker and examine whether C4d plasma levels correlate with treatment response and C4d kidney deposition in systemic lupus erythematosus (SLE) with lupus nephritis…
- Trial name
- NCT05082363
- Testing
- C4d evaluation in lupus nephritis in serum and renal tissue
- Volunteers
- 30 people
- Sponsor
- Assiut University